Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
413 participants
OBSERVATIONAL
2022-10-05
2023-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: This descriptive and cross-sectional study was conducted on 413 women. This research was conducted between October 2022 and July 2023 in the central district of a province in the northwestern region of Türkiye. The data were collected using a Personal Information Form and the Incontinence Quality of Life. The data were analyzed using the Statistical Package for Social Sciences (SPSS for Windows, IBM, version 22.0) at a significance level of 0.05. Descriptive statistics baseline characteristics. Normality was tested using the Kolmogorov-Smirnov test. The results showed that the data were normally distributed. Therefore, an independent t-test (t-table value) was used for two independent groups, while an Analysis of Variance (ANOVA) (F-table value) was used for more than two groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women with Urinary Incontinence
NCT06866834
Posture, Core Stabilization, Respiratory Muscle Strength and Quality of Life in Women With Urinary Incontinence
NCT06988683
Comparison of Single Voiding Cycle and Two and Three Voiding Cycles in Ambulatory Urodynamic Studies
NCT05666063
Prevalence of Urinary Incontinence in Different Age Categories
NCT00906607
Living With Urinary Incontinence: Women's Experiences in a Qualitative Phenomenological Study
NCT06421428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Urinary incontinence constitutes a significant public health issue when considering the global female population, their participation in the workforce, and their role in social life.6 Urinary incontinence afflicts more than 40% of women worldwide.7 (Liu et al., 2014). The prevalence of UI is 48.3%, 46.4%, 31.9%, and 18.7% in women over 18 years of age living in Germany, Denmark, China, and Norway, respectively.8-10 The prevalence of UI is 23.6% in women aged 45-60 years living in Brazil.11 The prevalence of UI ranges from 16.4% and 49.7 in Turkish women.12 The projected number of women with UI in the United States is expected to reach 28.4 million by 2050.13 Investigators believe that the prevalence of UI may be underestimated because many women either seek healthcare assistance late or not at all due to perceiving it as a natural consequence of aging or childbirth or because they feel embarrassed about the issue. Furthermore, only a small fraction of women who are diagnosed with UI receive effective treatment.2,3,14 More than half of women with UI (66.4%) take approximately three years to seek medical assistance due to fears of stigmatization and a lack of information about treatment.4,15 The treatment and care for UI necessitate a multidisciplinary approach due to the complexity of the condition and the various issues it involves. However, before women are willing to seek medical assistance for UI, they must first recognize it as a medical issue. Hence, it is essential to develop a comprehensive understanding of UI, raise awareness among women about the condition, and provide ongoing support for those affected by it. By taking these steps, we can effectively manage and prevent this condition, as well as create opportunities for early diagnosis and treatment. Therefore, this study investigated the prevalence, type, and risk factors of UI in married women and its effect on their quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Description
All patients were briefed about the research purpose and procedure. They were also informed about the following points: (1) participation is voluntary, (2) they can withdraw from the study at any stage without explanation, (3) the data will be used only for scientific purposes and will not be shared with third parties, and (4) they will remain anonymous throughout the research. Informed consent was obtained from those who agreed to participate. It took each participant 20-25 minutes to fill out the data collection tools.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kastamonu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MAHİNUR DURMUŞ İSKENDER
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kastamonu University
Kastamonu, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDURMUSISKENDER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.